Cefotaxime

C difficile risk
High
Oral Bioavailability
N/A

Dosing

1 - 2 g IV q6 - 8h

Infuse over 20 minutes

Age 0-4 wk50 mg/kg/dose IV Q12H

Age 0-7 days>7 days50 mg/kg/dose IV Q12H50 mg/kg/dose IV Q8H

Age 0-7 days>7 days50 mg/kg/dose IV Q12H50 mg/kg/dose IV Q8H

All Infants: 50 mg/kg/dose IV Q8H

IV, IM

100 mg/mL

Reconstitute 500mg vial with 5mL of sterile water for injection = 100 mg/mL

24H Refrigerate

0 - 30 eGFR30 - 50 eGFR50+ eGFR1 - 2 g IV q12 - 24h1 - 2 g IV q8 - 12h1 - 2 g IV q6 - 8h

Increase dosing interval in renal impairment

General Information

Empiric therapy for bacterial meningitis, pneumonia, intra-abdominal infection, musculoskeletal i.e. septic arthritis, and urinary tract infection.

Pregnancy: Compatible.

Breastfeeding: Compatible.

  • Rash, localized phlebitis at injection site, allergy.

  • Positive Coombs test, neutropenia, abnormalities in liver enzymes.

  • Diarrhea and CDI.

Cefotaxime is the preferred 3rd generation cephalosporin vs ceftriaxone in pregnant patients near delivery (particularly preterm delivery) to minimize ceftriaxone exposure in the newborn.

Antimicrobial class: 3rd Generation Cephalosporin